Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury

Ronald P. Sutsko, Karen Young, Ana Ribeiro, Eneida Torres, Myra Rodriguez, Dorothy Hehre, Carlos Devia, Ian McNiece, Cleide Suguihara

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Mesenchymal stem cell (MSC) therapy may prevent neonatal hyperoxia-induced lung injury (HILI). There are, however, no clear data on the therapeutic efficacy of MSC therapy in established HILI, the duration of the reparative effects, and the exact mechanisms of repair. The main objective of this study was to evaluate whether the long-term reparative effects of a single intratracheal (IT) dose of MSCs or MSC-conditioned medium (CM) are comparable in established HILI.Methods:Newborn rats exposed to normoxia or hyperoxia from postnatal day (P)2)-P16 were randomized to receive IT MSCs, IT CM, or IT placebo (PL) on P9. Alveolarization and angiogenesis were evaluated at P16, P30, and P100.Results:At all time periods, there were marked improvements in alveolar and vascular development in hyperoxic pups treated with MSCs or CM as compared with PL. This was associated with decreased expression of inflammatory mediators and an upregulation of angiogenic factors. Of note, at P100, the improvements were more substantial with MSCs as compared with CM.Conclusion:These data suggest that acute effects of MSC therapy in HILI are mainly paracrine mediated; however, optimum long-term improvement following HILI requires treatment with the MSCs themselves or potentially repetitive administration of CM.

Original languageEnglish
Pages (from-to)46-53
Number of pages8
JournalPediatric Research
Volume73
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Hyperoxia
Lung Injury
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Conditioned Culture Medium
Placebos
Angiogenesis Inducing Agents
Blood Vessels
Up-Regulation
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury. / Sutsko, Ronald P.; Young, Karen; Ribeiro, Ana; Torres, Eneida; Rodriguez, Myra; Hehre, Dorothy; Devia, Carlos; McNiece, Ian; Suguihara, Cleide.

In: Pediatric Research, Vol. 73, No. 1, 01.01.2013, p. 46-53.

Research output: Contribution to journalArticle

Sutsko, RP, Young, K, Ribeiro, A, Torres, E, Rodriguez, M, Hehre, D, Devia, C, McNiece, I & Suguihara, C 2013, 'Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury', Pediatric Research, vol. 73, no. 1, pp. 46-53. https://doi.org/10.1038/pr.2012.152
Sutsko, Ronald P. ; Young, Karen ; Ribeiro, Ana ; Torres, Eneida ; Rodriguez, Myra ; Hehre, Dorothy ; Devia, Carlos ; McNiece, Ian ; Suguihara, Cleide. / Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury. In: Pediatric Research. 2013 ; Vol. 73, No. 1. pp. 46-53.
@article{8dfd427054164a7da0a35f252830eafd,
title = "Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury",
abstract = "Mesenchymal stem cell (MSC) therapy may prevent neonatal hyperoxia-induced lung injury (HILI). There are, however, no clear data on the therapeutic efficacy of MSC therapy in established HILI, the duration of the reparative effects, and the exact mechanisms of repair. The main objective of this study was to evaluate whether the long-term reparative effects of a single intratracheal (IT) dose of MSCs or MSC-conditioned medium (CM) are comparable in established HILI.Methods:Newborn rats exposed to normoxia or hyperoxia from postnatal day (P)2)-P16 were randomized to receive IT MSCs, IT CM, or IT placebo (PL) on P9. Alveolarization and angiogenesis were evaluated at P16, P30, and P100.Results:At all time periods, there were marked improvements in alveolar and vascular development in hyperoxic pups treated with MSCs or CM as compared with PL. This was associated with decreased expression of inflammatory mediators and an upregulation of angiogenic factors. Of note, at P100, the improvements were more substantial with MSCs as compared with CM.Conclusion:These data suggest that acute effects of MSC therapy in HILI are mainly paracrine mediated; however, optimum long-term improvement following HILI requires treatment with the MSCs themselves or potentially repetitive administration of CM.",
author = "Sutsko, {Ronald P.} and Karen Young and Ana Ribeiro and Eneida Torres and Myra Rodriguez and Dorothy Hehre and Carlos Devia and Ian McNiece and Cleide Suguihara",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/pr.2012.152",
language = "English",
volume = "73",
pages = "46--53",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Long-term reparative effects of mesenchymal stem cell therapy following neonatal hyperoxia-induced lung injury

AU - Sutsko, Ronald P.

AU - Young, Karen

AU - Ribeiro, Ana

AU - Torres, Eneida

AU - Rodriguez, Myra

AU - Hehre, Dorothy

AU - Devia, Carlos

AU - McNiece, Ian

AU - Suguihara, Cleide

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Mesenchymal stem cell (MSC) therapy may prevent neonatal hyperoxia-induced lung injury (HILI). There are, however, no clear data on the therapeutic efficacy of MSC therapy in established HILI, the duration of the reparative effects, and the exact mechanisms of repair. The main objective of this study was to evaluate whether the long-term reparative effects of a single intratracheal (IT) dose of MSCs or MSC-conditioned medium (CM) are comparable in established HILI.Methods:Newborn rats exposed to normoxia or hyperoxia from postnatal day (P)2)-P16 were randomized to receive IT MSCs, IT CM, or IT placebo (PL) on P9. Alveolarization and angiogenesis were evaluated at P16, P30, and P100.Results:At all time periods, there were marked improvements in alveolar and vascular development in hyperoxic pups treated with MSCs or CM as compared with PL. This was associated with decreased expression of inflammatory mediators and an upregulation of angiogenic factors. Of note, at P100, the improvements were more substantial with MSCs as compared with CM.Conclusion:These data suggest that acute effects of MSC therapy in HILI are mainly paracrine mediated; however, optimum long-term improvement following HILI requires treatment with the MSCs themselves or potentially repetitive administration of CM.

AB - Mesenchymal stem cell (MSC) therapy may prevent neonatal hyperoxia-induced lung injury (HILI). There are, however, no clear data on the therapeutic efficacy of MSC therapy in established HILI, the duration of the reparative effects, and the exact mechanisms of repair. The main objective of this study was to evaluate whether the long-term reparative effects of a single intratracheal (IT) dose of MSCs or MSC-conditioned medium (CM) are comparable in established HILI.Methods:Newborn rats exposed to normoxia or hyperoxia from postnatal day (P)2)-P16 were randomized to receive IT MSCs, IT CM, or IT placebo (PL) on P9. Alveolarization and angiogenesis were evaluated at P16, P30, and P100.Results:At all time periods, there were marked improvements in alveolar and vascular development in hyperoxic pups treated with MSCs or CM as compared with PL. This was associated with decreased expression of inflammatory mediators and an upregulation of angiogenic factors. Of note, at P100, the improvements were more substantial with MSCs as compared with CM.Conclusion:These data suggest that acute effects of MSC therapy in HILI are mainly paracrine mediated; however, optimum long-term improvement following HILI requires treatment with the MSCs themselves or potentially repetitive administration of CM.

UR - http://www.scopus.com/inward/record.url?scp=84872086190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872086190&partnerID=8YFLogxK

U2 - 10.1038/pr.2012.152

DO - 10.1038/pr.2012.152

M3 - Article

C2 - 23138401

AN - SCOPUS:84872086190

VL - 73

SP - 46

EP - 53

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 1

ER -